Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
ThesisBavarian Nordic A/S: the story is balanced — Mpox outbreak developments and government vaccine procurement announcements - drives 30-50% revenue swings
★ Analysts see FY2027 revenue reaching $5.7B — -3.1% growth in a single year.
What Moves the Stock
01Mpox outbreak developments and government vaccine procurement announcements - drives 30-50% revenue swings
02US and European government stockpiling contract renewals and order timing - typically multi-year agreements worth $100M-500M+
03Clinical trial readouts for pipeline candidates including cancer immunotherapy programs (CV301, CV302)
04Travel vaccine market share gains and geographic expansion, particularly in Asia-Pacific markets
05FDA/EMA regulatory decisions on label expansions or new vaccine approvals
06Mpox/smallpox vaccines (JYNNEOS/Imvanex) - historically 60-80% of revenue during outbreak periods, normalizing to lower baseline government stockpiling contracts
07Travel vaccines including rabies (Rabipur/RabAvert) and tick-borne encephalitis - estimated 15-25% of normalized revenue
08Contract manufacturing and development services for government and commercial partners - estimated 10-15% of revenue
value - The stock attracts opportunistic value investors following the post-outbreak revenue decline…
Rising interest rates have moderate negative impact through two channels: (1) higher discount rates compress valuation multiples for biotech…
Watch on earnings: WHO and CDC mpox case counts and outbreak declarations - leading indicator for vaccine demand, US HHS and European government budget allocations for biodefense preparedness programs, JYNNEOS order backlog and contract award announcements from BARDA and European procurement agencies.
One Sentence Summary:
Bavarian Nordic A/S: the story is balanced — mpox outbreak developments and government vaccine procurement announcements - drives 30-50% revenue swings.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
